Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
about
In vitro hydroxyurea decreases Th1 cell-mediated immunityHigh-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsNucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.Altered strand transfer activity of a multiple-drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutant with a dipeptide fingers domain insertion.Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
P2860
Q28367791-81A20160-033D-40D8-87D8-B483608A21A2Q33796791-567DCA5E-24EB-4942-9D9E-1FB00E79A759Q33820365-9B331703-886D-4DA3-B9B8-509CD57CFDE9Q33826453-FD48FE69-DEE5-4868-A207-F6265376251FQ33841974-AEDF6096-D568-49B9-9B03-ED7C7E839E02Q33896402-4CE765DE-FD06-45F6-8226-4C33FE7BDCF3Q33982354-6F3FFEDE-18C0-4D7F-AE0D-CE26D1E8971DQ34345605-9B7B7D1B-BEC6-4834-82F8-5969268E30F9Q34348774-DAACFA2D-46C6-4B3F-B4E8-AFC7B41F6E05Q34717892-522EF6D0-E6C9-47AF-AB4D-6729CA6B983CQ36175788-35D691A7-126A-4E56-B1B2-45FBB56FF629Q37387866-A61BD1F3-2EF1-4B78-BC5B-C5BFC6829F2FQ39471491-F0D473D0-4DC8-4A08-A448-AB114F638B99Q39471555-04DF6EA7-250D-4487-94D4-1177C6E13EFCQ39585504-FF863D69-D8AB-497D-898F-E1226BFA6A4CQ39657878-55EE1D10-E39B-4E77-925B-974FF13246FCQ39730755-993FC64D-7454-4402-98ED-E91DB8E1B44DQ39912641-26963B56-3D32-44B1-8676-329636800C2AQ40388003-3D0F76E7-C994-4261-B4B4-003C850A87B7Q41911362-46904D33-465E-4D35-AF88-CCE9667AEE2AQ42737965-E84E52E6-EEB8-41CD-B1F5-803E0772F7C5
P2860
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Mutations in the pol gene of h ...... droxyurea combination therapy.
@en
Mutations in the pol gene of h ...... droxyurea combination therapy.
@nl
type
label
Mutations in the pol gene of h ...... droxyurea combination therapy.
@en
Mutations in the pol gene of h ...... droxyurea combination therapy.
@nl
prefLabel
Mutations in the pol gene of h ...... droxyurea combination therapy.
@en
Mutations in the pol gene of h ...... droxyurea combination therapy.
@nl
P2093
P1476
Mutations in the pol gene of h ...... droxyurea combination therapy.
@en
P2093
P304
P407
P577
1997-10-01T00:00:00Z